Go to content

Publications

443 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. Organisation chart 2023

    Organisation chart 2023

    Publication | 13-10-2023

  2. Conditional inclusion procedure for medicinal products

    This document describes the conditional inclusion procedure for orphan drugs, conditionals and exceptionals.

    Publication | 29-09-2023

  3. Advice on a possible candidate for the conditional inclusion of teduglutide (Revestive®)

    The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to designate teduglutide (Revestive®) ...

    Report | 21-09-2023

  4. Package advice for the lock procedure medicinal product zanubrutinib (Brukinsa®) for the treatment of chronic lymphocytic leukaemia (CLL)

    The National Health Care Institute has assessed whether the CGRP inhibitor eptinezumab (Vyepti®) can be reimbursed from the basic ...

    Report | 31-08-2023

  5. GVS advice fenfluramine (Fintepla®) for the treatment of epileptic seizures in Dravet Syndrome or Lennox-Gastaut Syndrome

    The National Health Care Institute has assessed whether fenfluramine (Fintepla®) can be included in the Medicine Reimbursement ...

    Report | 31-08-2023

  6. GVS advice midazolam (Midazolam Xiromed®) for the treatment of epilepsy

    The National Health Care Institute has assessed whether oromucosal administration of midazolam (Midazolam Xiromed®) can be ...

    Report | 22-08-2023

  7. GVS advice tezepelumab (Tezspire®) for the treatment of patients 12 years and older with severe asthma

    The National Health Care Institute has assessed whether tezepelumab (Tezspire®) can be included in the Medicine Reimbursement ...

    Letter | 17-08-2023

  8. GVS advice for tirzepatide (Mounjaro®) for the treatment of adults with type 2 diabetes mellitus without a very high risk of cardiovascular disease

    The National Health Care Institute has assessed whether tirzepatide (Mounjaro®) can be included in the Medicine Reimbursement ...

    Report | 14-08-2023

  9. Advice - Extension of conditional inclusion procedure for ataluren (Translarna®)

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to extend the conditional ...

    Report | 31-07-2023

  10. GVS advice glucagon (Ogluo®) for the treatment of severe hypoglycaemia in adults and children aged 2 years and older

    The National Health Care Institute assessed whether the administration of subcutaneous glucagon (administration under the skin) ...

    Report | 28-07-2023

Go to